Form 6K Alvotech SA For: 11 May
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alvotech SA (ALVO)
Assess today's live Alvotech SA (ALVO) share price, performance and insights using our live NASDAQ: ALVO stock exchange data.
Analyse the historical data and Alvotech SA share price performance charts on this page. Our technical summary section provides analysis on Alvotech share price buy/sell indicators using real-time data (or discuss the Alvotech (ALVO) stock price today with other investors in the Alvotech NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ALVO share price (ISIN: LU2458332611) to enhance your trading decisions with our free investment tools and resources.
What Is the Alvotech SA Share Price Today?
The Alvotech share price today is 3.28.
What Is the Stock Symbol for Alvotech SA
The stock symbol (or 'ticker') for Alvotech SA is "ALVO."
What Stock Exchange Does Alvotech SA Trade On?
Alvotech SA is listed and trades on the NASDAQ stock exchange.
Is Alvotech SA a Good Stock to Buy?
Determining whether Alvotech SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Alvotech SA share price performance charts on this page. Our technical summary section provides analysis on Alvotech share price buy/sell indicators using real-time data (or discuss the Alvotech (ALVO) stock price today with other investors in the Alvotech NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ALVO share price (ISIN: LU2458332611) to enhance your trading decisions with our free investment tools and resources.
What Is the Alvotech SA Share Price Today?
The Alvotech share price today is 3.28.
What Is the Stock Symbol for Alvotech SA
The stock symbol (or 'ticker') for Alvotech SA is "ALVO."
What Stock Exchange Does Alvotech SA Trade On?
Alvotech SA is listed and trades on the NASDAQ stock exchange.
Is Alvotech SA a Good Stock to Buy?
Determining whether Alvotech SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.20
3.32
52 wk Range
3.03
11.85
ALVO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.203.32
52 wk Range
3.0311.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALVO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
13.83
Upside
+321.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
1 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 13.83
(+321.75% Upside)
Alvotech SA SWOT Analysis
Biosimilar Pionee | Alvotech emerges as a potential top-3 global biosimilars pureplay, leveraging a unique B2B model in a competitive pharmaceutical landscape |
Financial Trajectory | Despite current negative EPS, Alvotech projects strong growth with Q3 2024 revenue forecast at $93 million and positive EPS expected in the second fiscal yea |
Product Portfolio | Explore Alvotech's key products Simlandi and Selardsi, alongside three upcoming BLA filings, driving the company's market expansion and revenue growth strategies |
Market Valuation | Analysts maintain an $18 price target, reflecting confidence in Alvotech's long-term potential despite current profitability challenges and market uncertainties |
Alvotech SA Earnings Call Summary for Q1/2026
- Q1 2026 EPS of -$0.09 missed forecast of $0.0015; revenue fell 20% YoY to $106M, below $130.89M estimate due to manufacturing slowdowns.
- Stock dropped 7.28% in premarket to $3.31, near 52-week low of $3.03, as investors reacted to significant earnings miss and revenue shortfall.
- Adjusted EBITDA rose to $24M from $21M YoY despite challenges; gross margin improved to 57%, showing operational resilience amid headwinds.
- Company projects stronger Q4 2026 performance with positive free cash flow by year-end; expects 2027 growth from product launches and initiatives.
- CEO Wessman cited operational excellence improvements; risks include ongoing manufacturing issues, regulatory delays, and market saturation concerns.
Last Updated: 07/05/2026, 14:02
Read Full TranscriptEarnings
Latest Release
06/05/2026
EPS / Forecast
-0.09 / 0.00
Revenue / Forecast
105.9M / 130.89M
Compare ALVO to Peers and Sector
Metrics to compare | ALVO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALVOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.7x | 12.1x | −0.5x | |
PEG Ratio | 0.07 | 0.06 | 0.00 | |
Price/Book | −3.6x | 3.5x | 2.6x | |
Price / LTM Sales | 1.8x | 3.9x | 3.1x | |
Upside (Analyst Target) | 128.7% | 215.4% | 55.1% | |
Fair Value Upside | Unlock | 14.1% | 7.2% | Unlock |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Alvotech (NASDAQ: ALVO) Share Price Today?
The Alvotech stock price today is 3.28 USD.
What Stock Exchange Does Alvotech (ALVO) Trade On?
Alvotech is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Alvotech?
The stock symbol (also called a 'ticker') for Alvotech is "ALVO."
What Is the Current Alvotech Market Capitalisation?
As of today, Alvotech (NASDAQ: ALVO) market cap is 1.03B USD.
What Is Alvotech's (ALVO) Earnings Per Share (TTM)?
The Alvotech EPS is currently -0.26 (Trailing Twelve Months).
When Is the Next Alvotech Earnings Date?
Alvotech's next earnings report will be released on 19/08/2026.
Is ALVO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Alvotech moving averages and other technical indicators, the daily buy/sell signal for ALVO stock is Strong Sell.
How Many Times Has Alvotech Stock Split?
Alvotech has split 0 times. (See the ALVO stock split history page for full effective split date and price information.)
How Many Employees Does Alvotech Have?
Alvotech has 1279 employees, based on their latest Companies House report.
What is the current trading status of Alvotech (NASDAQ: ALVO)?
As of 20/05/2026, Alvotech (ALVO) is trading at a share price of 3.28 USD, with a previous close of 3.28 USD. The stock has fluctuated within a day range of 3.20 USD to 3.32 USD, while its 52-week range spans from 3.03 USD to 11.85 USD.
What Is Alvotech (ALVO) Price Target According to Analysts?
The average 12-month price target for Alvotech is 13.83 USD, with a high estimate of 50 USD and a low estimate of 4 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +321.75% Upside potential.
What Is the ALVO After Hours Price?
ALVO's last after hours stock price is 3.26 USD, the stock has decreased by -0.02, or -0.56%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.